No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
DXC240621P20000
- 1.50
- -2.90-65.91%
15min DelayTrading Jun 20 09:30 ET
1.50High1.50Low
1.50Open4.40Pre Close4 Volume317 Open Interest20.00Strike Price600.00Turnover109.31%IV-0.38%PremiumJun 21, 2024Expiry Date1.57Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8645Delta0.1633Gamma11.52Leverage Ratio-0.0754Theta-0.0007Rho-9.96Eff Leverage0.0027Vega
Intraday
- 5D
- Daily
News
Express News | Reported Wednesday, Checkmarx And DXC Technology Enhance Collaboration To Offer Scalable Application Security Worldwide
The Past Five Years for DXC Technology (NYSE:DXC) Investors Has Not Been Profitable
Checkmarx and DXC Technology Team Up to Deliver Scalable, Holistic Application Security Worldwide
Enhanced collaboration will reduce risk, improve software quality and accelerate digital transformation and cloud migration for global enterprises Checkmarx, the industry leader in cloud-native application security
Form 144 | DXC Technology(DXC.US) Insider Proposes to Sell 614.98K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 17, $DXC Technology(DXC.US)$ Insider DECKELMAN WILLIAM L JR intends to sell 34,764 shares of its common stock on Jun 17, with a total market value of approximately $614.98K
In-Depth Examination Of 8 Analyst Recommendations For DXC Technology
In the last three months, 8 analysts have published ratings on DXC Technology (NYSE:DXC), offering a diverse range of perspectives from bullish to bearish.Summarizing their recent assessments, the tab
DXC Technology Is Maintained at Neutral by Susquehanna
DXC Technology Is Maintained at Neutral by Susquehanna
Comments
Morning Movers
Gapping up
$Eli Lilly and Co(LLY.US$ shares rose 2% after a panel of FDA advisors recommended the approval of its Alzheimer's drug known as donanemab.
$General Motors(GM.US$ The automaker's stock added more than 1% after its board authorized a $6 billion stock buyback program.
$Shopify(SHOP.US$ The e-commerce stock rose about 1% after JPMorgan initiated coverage with an overweight rating, stating that the recen...
Gapping up
$Eli Lilly and Co(LLY.US$ shares rose 2% after a panel of FDA advisors recommended the approval of its Alzheimer's drug known as donanemab.
$General Motors(GM.US$ The automaker's stock added more than 1% after its board authorized a $6 billion stock buyback program.
$Shopify(SHOP.US$ The e-commerce stock rose about 1% after JPMorgan initiated coverage with an overweight rating, stating that the recen...
Expand 33
Morning Movers
Gapping up
$Reddit(RDDT.US$ stock increased by 12% as the company announced a partnership with OpenAI to incorporate its content into the AI firm's products.
$Tesla(TSLA.US$ 's stock inched up 0.1% following reports that the company is advancing its use of China-collected data to enhance the development of its autonomous driving technology globally.
$Boeing(BA.US$ 's stock saw a modest uptick of 0.2% ahead o...
Gapping up
$Reddit(RDDT.US$ stock increased by 12% as the company announced a partnership with OpenAI to incorporate its content into the AI firm's products.
$Tesla(TSLA.US$ 's stock inched up 0.1% following reports that the company is advancing its use of China-collected data to enhance the development of its autonomous driving technology globally.
$Boeing(BA.US$ 's stock saw a modest uptick of 0.2% ahead o...
26
2
Recent insider selling at DXC Technology, along with no insider buying in the past year, raises caution. Despite a reasonable degree of alignment due to insider ownership, the absence of insider buying and recent selling prompts caution about the company.
1
DXC Technology's CEO, Raul Fernandez, is thrilled about Fawcett's appointment, emphasizing his extensive technology and software experience. Fernandez is confident that Fawcett's experience will be instrumental for DXC's upcoming growth phase.
1
The company's significant liabilities and EBIT loss of US$790m over the last year raise concerns about its financial health. Without near-term improvements, the stock is considered risky.
Read more